Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons.
Saved in:
| Title: | Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons. |
|---|---|
| Authors: | Ison MG; Bethesda, Maryland, USA., Papi A; Pulmonary Division, University of Ferrara, St. Anna University Hospital, Ferrara, Italy., Athan E; Barwon Health, University Hospital Geelong, Geelong, Australia.; Centre for Innovation in Infectious Diseases and Immunology Research, Deakin University, Geelong, Australia., Feldman RG; Senior Clinical Trials, Inc, Laguna Hills, California, USA., Langley JM; Canadian Center for Vaccinology, Dalhousie University, IWK Health and Nova Scotia Health, Halifax, Canada., Lee DG; Division of Infectious Diseases, Department of Internal Medicine, Vaccine Bio Research Institute, College of Medicine, The Catholic University of Korea, Seoul, South Korea., Leroux-Roels I; Center for Vaccinology, Ghent University and Ghent University Hospital, Ghent, Belgium., Martinon-Torres F; Translational Pediatrics and Infectious Diseases, Pediatrics Department, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain.; Genetics, Vaccines, Infectious Diseases, and Pediatrics Research Group, Instituto de Investigación Sanitaria de Santiago, Universidad de Santiago de Compostela, Santiago de Compostela, Spain.; Consorcio Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain., Schwarz TF; Institute of Laboratory Medicine and Vaccination Center, Klinikum Würzburg Mitte, Campus Juliusspital, Würzburg, Germany., van Zyl-Smit RN; Division of Pulmonology and University of Cape Town Lung Institute, Department of Medicine, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa., Verheust C; GSK, Wavre, Belgium., Dezutter N; GSK, Wavre, Belgium., Gruselle O; GSK, Wavre, Belgium., Fissette L; GSK, Wavre, Belgium., David MP; GSK, Wavre, Belgium., Kostanyan L; GSK, Wavre, Belgium., Hulstrøm V; GSK, Wavre, Belgium., Olivier A; GSK, Wavre, Belgium., Van der Wielen M; GSK, Wavre, Belgium., Descamps D; GSK, Wavre, Belgium. |
| Corporate Authors: | AReSVi-006 Study Group |
| Source: | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2024 Jun 14; Vol. 78 (6), pp. 1732-1744. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 9203213 Publication Model: Print Cited Medium: Internet ISSN: 1537-6591 (Electronic) Linking ISSN: 10584838 NLM ISO Abbreviation: Clin Infect Dis Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1537-6591 |
|---|---|
| DOI: | 10.1093/cid/ciae010 |
